$BICX
BioCorRx Inc. Stock $bicx

$bicx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000147793224001705 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.620K	$18.94K	$89.16K
YoY Change	-91.05%	-77.15%	-58.31%
Cost Of Revenue	$1.667K	$13.05K	$35.99K
YoY Change	-80.79%	50.35%	89.94%
Gross Profit	$1.953K	$5.890K	$53.17K
YoY Change	-93.85%	-92.06%	-72.72%
Gross Profit Margin	53.95%	31.1%	59.64%
Selling, General & Admin	$750.1K	$693.6K	$2.875M
YoY Change	-5.77%	-3.28%	-15.68%
% of Gross Profit	38407.48%	11775.72%	5407.0%
Research & Development	$213.8K	$128.3K	$891.1K
YoY Change	-9.92%	-76.07%	-38.95%
% of Gross Profit	10949.0%	2178.27%	1675.75%
Depreciation & Amortization	$6.419K	$6.810K	$25.63K
YoY Change	0.77%	-0.73%	-6.63%
% of Gross Profit	328.67%	115.62%	48.2%
Operating Expenses	$972.3K	$828.6K	$3.877M
YoY Change	-11.35%	-34.24%	-21.07%
Operating Profit	-$968.7K	-$822.7K	-$3.788M
YoY Change	-8.3%	-30.62%	-19.37%
Interest Expense	$181.8K	-$294.4K	$194.0K
YoY Change	598.23%	51.42%	28.53%
% of Operating Profit
Other Income/Expense, Net	-$268.8K	$148.1K	$17.31K
YoY Change	-687.75%	-31.82%	-94.61%
Pretax Income	-$1.237M	-$969.0K	-$3.770M
YoY Change	22.45%	-16.68%	-13.85%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.237M	-$968.5K	-$3.770M
YoY Change	22.45%	-16.49%	-13.85%
Net Earnings / Revenue	-34184.06%	-5113.73%	-4228.9%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.14	-$0.11	-$0.45
COMMON SHARES
Basic Shares Outstanding	8.815M shares	8.599M shares
Diluted Shares Outstanding	2.941M shares		2.697M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$101.1K	$65.22K	$65.22K
YoY Change	-50.38%	-4.95%	-4.95%
Cash & Equivalents	$101.1K	$65.22K
Short-Term Investments
Other Short-Term Assets	$29.47K	$44.89K	$44.89K
YoY Change	-48.07%	-45.77%	-45.77%
Inventory
Prepaid Expenses	$29.47K	$44.89K
Receivables	$0.00	$740.00	$77.01K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$151.6K	$187.1K	$187.1K
YoY Change	-55.99%	-40.96%	-40.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.52K	$50.94K	$148.2K
YoY Change	-36.58%	-33.47%	-57.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$41.94K	$44.52K	$44.52K
YoY Change	-5.8%	0.0%	0.0%
Total Long-Term Assets	$165.9K	$201.8K	$201.8K
YoY Change	-54.53%	-55.13%	-55.13%
TOTAL ASSETS
Total Short-Term Assets	$151.6K	$187.1K	$187.1K
Total Long-Term Assets	$165.9K	$201.8K	$201.8K
Total Assets	$317.4K	$388.9K	$388.9K
YoY Change	-55.24%	-49.27%	-49.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.773M	$2.473M	$2.473M
YoY Change	26.66%	22.86%	22.86%
Accrued Expenses	$2.308M	$2.298M	$2.298M
YoY Change	9.87%	13.28%	13.28%
Deferred Revenue
YoY Change
Short-Term Debt	$2.007M	$1.606M	$1.606M
YoY Change	30.46%		24.65%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.168M	$6.431M	$6.431M
YoY Change	22.47%	19.9%	19.9%
LONG-TERM LIABILITIES
Long-Term Debt	$72.11K	$72.47K	$72.47K
YoY Change	-1.9%	-1.87%	-1.87%
Other Long-Term Liabilities	$3.945M	$3.838M	$3.838M
YoY Change	9.3%	8.7%	8.7%
Total Long-Term Liabilities	$4.017M	$3.910M	$3.910M
YoY Change	9.07%	8.48%	8.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.168M	$6.431M	$6.431M
Total Long-Term Liabilities	$4.017M	$3.910M	$3.910M
Total Liabilities	$11.19M	$10.34M	$10.21M
YoY Change	17.3%	15.31%	15.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.34M	-$78.10M
YoY Change	5.3%	5.07%
Common Stock	$8.897K	$8.674K
YoY Change	9.8%	12.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.74M	-$9.824M	-$9.824M
YoY Change
Total Liabilities & Shareholders Equity	$317.4K	$388.9K	$388.9K
YoY Change	-55.24%	-49.27%	-49.27%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.237M	-$968.5K	-$3.770M
YoY Change	22.45%	-16.49%	-13.85%
Depreciation, Depletion And Amortization	$6.419K	$6.810K	$25.63K
YoY Change	0.77%	-0.73%	-6.63%
Cash From Operating Activities	-$339.7K	-$533.3K	-$1.853M
YoY Change	-14.52%	18.62%	-9.23%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$375.5K	439.9K	$1.850M
YoY Change	-29.47%	-3.25%	-8.63%
NET CHANGE
Cash From Operating Activities	-$339.7K	-533.3K	-$1.853M
Cash From Investing Activities
Cash From Financing Activities	$375.5K	439.9K	$1.850M
Net Change In Cash	$35.86K	-93.39K	-$3.393K
YoY Change	-73.45%	-1934.77%	-80.3%
FREE CASH FLOW
Cash From Operating Activities	-$339.7K	-$533.3K	-$1.853M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	891063	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	130152	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	82765	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	187119	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	270406	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9027	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10206	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	53547	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	102706	usd
CY2023Q4	us-gaap	Assets Assets	388887	usd
CY2022Q4	us-gaap	Assets Assets	766594	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4649179	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3907954	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33256	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122732	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134343	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6431209	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5363792	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-33256	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	316910	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	44520	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	44520	usd
CY2022	us-gaap	Revenues Revenues	213841	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	35986	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	15279	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001443863
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8674029	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7718636	shares
CY2023Q4	bicx	Deferred Revenue Short Term DeferredRevenueShortTerm	4045	usd
CY2022Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1592197	usd
CY2023	bicx	Notes Payable Interest Rate NotesPayableInterestRate	0.08	pure
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	bicx	Total Lease Expense TotalLeaseExpense	112036	usd
CY2023Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	121774	usd
CY2022Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	121774	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	355662	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	887901	shares
CY2022	bicx	Outstanding At Ending OutstandingAtEnding	P3Y10M24D
CY2023Q1	bicx	Warrant Exercise Price Per Share WarrantExercisePricePerShare	4.00
CY2023Q2	bicx	Warrant Exercise Price Per Share WarrantExercisePricePerShare	4.00
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Entity File Number EntityFileNumber	000-54208
CY2023	dei	Entity Registrant Name EntityRegistrantName	BioCorRx Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0967447
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2390 East Orangewood Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Anaheim
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92806
CY2023	dei	City Area Code CityAreaCode	714
CY2023	dei	Local Phone Number LocalPhoneNumber	462-4880
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	9200147	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8815454	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65222	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68615	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	740	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35378	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	76266	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	44891	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50943	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	76572	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97278	usd
CY2023Q4	us-gaap	Development Costs Cumulative DevelopmentCostsCumulative	0	usd
CY2022Q4	us-gaap	Development Costs Cumulative DevelopmentCostsCumulative	47980	usd
CY2023Q4	bicx	Due To Related Party DueToRelatedParty	1683453	usd
CY2022Q4	bicx	Due To Related Party DueToRelatedParty	1077088	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	53460	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2023Q4	bicx	Debt Discount On Notes Payable DebtDiscountOnNotesPayable	354730	usd
CY2022Q4	bicx	Debt Discount On Notes Payable DebtDiscountOnNotesPayable	23878	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	606750	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	297602	usd
CY2023Q4	bicx	Debt Discount Related Parties DebtDiscountRelatedParties	77295	usd
CY2022Q4	bicx	Debt Discount Related Parties DebtDiscountRelatedParties	49473	usd
CY2023Q4	bicx	Notes Payable Current And Noncurrent NotesPayableCurrentAndNoncurrent	999088	usd
CY2022Q4	bicx	Notes Payable Current And Noncurrent NotesPayableCurrentAndNoncurrent	990637	usd
CY2023Q4	bicx	Economic Injury Disaster Loan Long Term EconomicInjuryDisasterLoanLongTerm	72466	usd
CY2022Q4	bicx	Economic Injury Disaster Loan Long Term EconomicInjuryDisasterLoanLongTerm	73850	usd
CY2023Q4	bicx	Discount On Royalty Obligation Related Parties DiscountOnRoyaltyObligationRelatedParties	4899354	usd
CY2022Q4	bicx	Discount On Royalty Obligation Related Parties DiscountOnRoyaltyObligationRelatedParties	5376790	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	3822746	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	3345310	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10945	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	181328	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4045	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4045	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10341411	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8968325	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8674029	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7718636	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8674	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7719	usd
CY2023Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100009	usd
CY2022Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68149029	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66130296	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78103018	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-74336105	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9823690	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8076474	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-128834	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-125257	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9952524	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8201731	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	388887	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	766594	usd
CY2023	us-gaap	Revenues Revenues	89160	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1459458	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2875119	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3409649	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	47980	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	26808	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27450	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	3876956	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4911836	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3787796	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4697995	usd
CY2023	bicx	Interest Expense Related Party Transactions InterestExpenseRelatedPartyTransactions	692586	usd
CY2022	bicx	Interest Expense Related Party Transactions InterestExpenseRelatedPartyTransactions	935806	usd
CY2023	us-gaap	Interest Expense InterestExpense	194041	usd
CY2022	us-gaap	Interest Expense InterestExpense	150969	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-34338	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-198939	usd
CY2023	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	322000	usd
CY2023	bicx	Grant Income GrantIncome	932996	usd
CY2022	bicx	Grant Income GrantIncome	1789496	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	5275	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	139381	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17306	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	321163	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3770490	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4376832	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3770490	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4376832	usd
CY2023	us-gaap	Noninterest Income NoninterestIncome	3577	usd
CY2022	us-gaap	Noninterest Income NoninterestIncome	7419	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-3766913	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-4369413	usd
CY2023	bicx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.45
CY2022	bicx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.61
CY2023	bicx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	8344079	shares
CY2022	bicx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	7198312	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6961476	usd
CY2022	bicx	Common Stock Issued In Connection With Subscription Agreement Amount CommonStockIssuedInConnectionWithSubscriptionAgreementAmount	1250000	usd
CY2022	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	243430	usd
CY2022	bicx	Warrants Issued In Connection With Loan Default WarrantsIssuedInConnectionWithLoanDefault	86821	usd
CY2022	bicx	Warrants Issued In Connection With Loan Default Related Party WarrantsIssuedInConnectionWithLoanDefaultRelatedParty	214975	usd
CY2022	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable Amount CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayableAmount	1062632	usd
CY2022	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes Amount CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotesAmount	167640	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	111079	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4376832	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8201731	usd
CY2023	bicx	Common Stock Issued In Connection With Subscription Agreement Amount CommonStockIssuedInConnectionWithSubscriptionAgreementAmount	915000	usd
CY2023	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	226435	usd
CY2023	bicx	Warrants Issued In Connection With Issuance Of Promissory Notes WarrantsIssuedInConnectionWithIssuanceOfPromissoryNotes	373127	usd
CY2023	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable Amount CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayableAmount	361892	usd
CY2023	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes Amount CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotesAmount	92623	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	50620	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3770490	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9952524	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-3770490	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-4376832	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	26808	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27450	usd
CY2023	bicx	Amortization Of Discount On Royalty Obligation AmortizationOfDiscountOnRoyaltyObligation	477436	usd
CY2022	bicx	Amortization Of Discount On Royalty Obligation AmortizationOfDiscountOnRoyaltyObligation	477436	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	166198	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17399	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	47980	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	173128	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	114515	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	277055	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	354509	usd
CY2023	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	322000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-34338	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-198939	usd
CY2023	bicx	Gain On Settlement Of Debt GainOnSettlementOfDebt	0	usd
CY2022	bicx	Gain On Settlement Of Debt GainOnSettlementOfDebt	133424	usd
CY2023	bicx	Noncash Interest For Debt Discount NoncashInterestForDebtDiscount	0	usd
CY2022	bicx	Noncash Interest For Debt Discount NoncashInterestForDebtDiscount	378686	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-34638	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33878	usd
CY2023	bicx	Increase Decrease In Grant Receivable IncreaseDecreaseInGrantReceivable	-53886	usd
CY2022	bicx	Increase Decrease In Grant Receivable IncreaseDecreaseInGrantReceivable	73793	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-37874	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1864	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	803117	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	838071	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-181994	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-119734	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-34981	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1853282	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2041773	usd
CY2023	bicx	Proceeds From Common Stock Subscription And Royalty Agreement ProceedsFromCommonStockSubscriptionAndRoyaltyAgreement	915000	usd
CY2022	bicx	Proceeds From Common Stock Subscription And Royalty Agreement ProceedsFromCommonStockSubscriptionAndRoyaltyAgreement	1250000	usd
CY2023	bicx	Payment To Economic Injury Disaster Loan PaymentToEconomicInjuryDisasterLoan	1384	usd
CY2022	bicx	Payment To Economic Injury Disaster Loan PaymentToEconomicInjuryDisasterLoan	450	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	35000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	600000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	371273	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	675000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1849889	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2024550	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3393	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-17223	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68615	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85838	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	65222	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	68615	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	17188	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	bicx	Common Stock Issued In Connection With Issuance Of Promissory Note CommonStockIssuedInConnectionWithIssuanceOfPromissoryNote	92623	usd
CY2022	bicx	Common Stock Issued In Connection With Issuance Of Promissory Note CommonStockIssuedInConnectionWithIssuanceOfPromissoryNote	167641	usd
CY2023	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayable	361892	usd
CY2022	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayable	1062632	usd
CY2023	bicx	Derivative Liability Recognized In Connection With Issuance Of Promissory Notes DerivativeLiabilityRecognizedInConnectionWithIssuanceOfPromissoryNotes	53460	usd
CY2022	bicx	Derivative Liability Recognized In Connection With Issuance Of Promissory Notes DerivativeLiabilityRecognizedInConnectionWithIssuanceOfPromissoryNotes	0	usd
CY2023	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotes	373127	usd
CY2022	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotes	0	usd
CY2023	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	20852	usd
CY2022	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	14360	usd
CY2023	bicx	Project Support Income ProjectSupportIncome	25817	usd
CY2022	bicx	Project Support Income ProjectSupportIncome	150578	usd
CY2023	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	33256	usd
CY2022	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	37293	usd
CY2023	bicx	Membership Program Fees MembershipProgramFees	9235	usd
CY2022	bicx	Membership Program Fees MembershipProgramFees	11610	usd
CY2023	us-gaap	Revenues Revenues	89160	usd
CY2022	us-gaap	Revenues Revenues	213841	usd
CY2022Q4	bicx	Deferred Revenue Short Term DeferredRevenueShortTerm	33256	usd
CY2022Q4	bicx	Deferred Revenue Long Term DeferredRevenueLongTerm	4045	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	37301	usd
CY2022Q4	bicx	Net Sales Recognized NetSalesRecognized	-33256	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	4045	usd
CY2023Q4	bicx	Deferred Revenue Long Term DeferredRevenueLongTerm	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions used in the fair value of other equity and debt instruments, income taxes, loss contingencies, and research and development costs.</p>
CY2023Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	53460	usd
CY2023Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	53460	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1853282	usd
CY2023	bicx	Gross Proceeds GrossProceeds	915000	usd
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	518801	shares
CY2023Q4	us-gaap	Share Price SharePrice	1.60
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	47980	usd
CY2023	bicx	Impairment Loss Software Development Costs ImpairmentLossSoftwareDevelopmentCosts	47980	usd
CY2023	bicx	Shares Underlying Options Outstanding SharesUnderlyingOptionsOutstanding	891443	usd
CY2022	bicx	Shares Underlying Options Outstanding SharesUnderlyingOptionsOutstanding	874058	usd
CY2023	bicx	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	1565856	shares
CY2022	bicx	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	333855	shares
CY2023	bicx	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	240000	shares
CY2022	bicx	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	240000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2697299	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1447913	shares
CY2023	us-gaap	Advertising Expense AdvertisingExpense	113170	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	325965	usd
CY2019Q1	bicx	Funding During First Year FundingDuringFirstYear	2842430	usd
CY2019Q1	bicx	Funding During Second Year FundingDuringSecondYear	2831838	usd
CY2019Q1	bicx	Grant Funding During The Third Year GrantFundingDuringTheThirdYear	3453367	usd
CY2019Q1	bicx	Grant Additional Funding During The Third Year GrantAdditionalFundingDuringTheThirdYear	99431	usd
CY2023Q4	bicx	Grant Receivables GrantReceivables	76266	usd
CY2022Q4	bicx	Grant Receivables GrantReceivables	122652	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	bicx	Grant Income GrantIncome	932996	usd
CY2022	bicx	Grant Income GrantIncome	1789496	usd
CY2023Q4	us-gaap	Direct To Television Film Costs Development DirectToTelevisionFilmCostsDevelopment	0	usd
CY2022Q4	us-gaap	Direct To Television Film Costs Development DirectToTelevisionFilmCostsDevelopment	253208	usd
CY2023	bicx	Grant Funding Indirect Cost GrantFundingIndirectCost	516218	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	891063	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1459458	usd
CY2023	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.50	pure
CY2023	bicx	Description Of Non Controlling Interest DescriptionOfNonControllingInterest	Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest. Due to the Company’s retaining 75.8% ownership of BioCorRx Pharmaceuticals, Inc., 75.8% of BioCorRx Pharmaceuticals, Inc.’s earnings was allocated to the Company, and 24.2% to the non-controlling interest
CY2023	bicx	Royalty Obligations Net Policy Textblock RoyaltyObligationsNetPolicyTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation and the gross projected future payments was $7,171,200 and was recorded as non-cash interest expense over the life of the liability and offset to additional paid in capital at inception.</p>
CY2023	bicx	Royalty Obligations Description RoyaltyObligationsDescription	The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued
CY2023	us-gaap	Royalty Expense RoyaltyExpense	7171200	usd
CY2023Q4	bicx	Working Capital Deficiency WorkingCapitalDeficiency	-6244090	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.53
CY2023	bicx	Outstanding Beginning OutstandingBeginning	P3Y10M24D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	559	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	8334	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	25719	shares
CY2023	bicx	Schedule Of Prepaid Expenses Table Textblock ScheduleOfPrepaidExpensesTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid insurance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,511</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,284</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid subscription services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,901</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,480</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Other prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">44,891</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">82,765</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	18511	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4284	usd
CY2023Q4	bicx	Prepaid Subscription Services PrepaidSubscriptionServices	26380	usd
CY2022Q4	bicx	Prepaid Subscription Services PrepaidSubscriptionServices	49901	usd
CY2023Q4	bicx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	usd
CY2022Q4	bicx	Prepaid Research And Development PrepaidResearchAndDevelopment	7480	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	21100	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	44891	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	82765	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	194551	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	194551	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	143608	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	117979	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50943	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	76572	usd
CY2023	us-gaap	Depreciation Depreciation	25629	usd
CY2022	us-gaap	Depreciation Depreciation	26271	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	500333	usd
CY2023Q4	bicx	Total Lease Liability TotalLeaseLiability	133677	usd
CY2022Q4	bicx	Total Lease Liability TotalLeaseLiability	315671	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122732	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134343	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10945	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	181328	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	129012	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11018	usd
CY2023Q4	bicx	Present Value Discount PresentValueDiscount	-6353	usd
CY2023Q4	bicx	Lease Liability LeaseLiability	133677	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	138932	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	144978	usd
CY2023	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	138932	usd
CY2022	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	144978	usd
CY2023	bicx	Total Lease Expense TotalLeaseExpense	147798	usd
CY2022	bicx	Total Lease Expense TotalLeaseExpense	150196	usd
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P1Y
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P2Y1M6D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1169	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1169	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1169	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1169	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	4351	usd
CY2023Q4	bicx	Total Future Amortization Of The Patents TotalFutureAmortizationOfThePatents	9027	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2473457	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2013250	usd
CY2023Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1268264	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1206753	usd
CY2023Q4	bicx	Interest Payable On Notes Payable Related Parties InterestPayableOnNotesPayableRelatedParties	478920	usd
CY2022Q4	bicx	Interest Payable On Notes Payable Related Parties InterestPayableOnNotesPayableRelatedParties	332567	usd
CY2023Q4	bicx	Accrual Of Loss On Contingency AccrualOfLossOnContingency	322000	usd
CY2022Q4	bicx	Accrual Of Loss On Contingency AccrualOfLossOnContingency	322000	usd
CY2023Q4	bicx	Interest Payable On Eidl Loan InterestPayableOnEidlLoan	5675	usd
CY2022Q4	bicx	Interest Payable On Eidl Loan InterestPayableOnEidlLoan	5860	usd
CY2023Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	43321	usd
CY2022Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	0	usd
CY2023Q4	bicx	Accrued Expenses AccruedExpenses	57542	usd
CY2022Q4	bicx	Accrued Expenses AccruedExpenses	27524	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4649179	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3907954	usd
CY2023Q4	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2023	us-gaap	Interest Expense InterestExpense	194041	usd
CY2022	us-gaap	Interest Expense InterestExpense	150969	usd
CY2023Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1268264	usd
CY2022Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1206753	usd
CY2023Q4	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2022Q4	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2023Q4	bicx	Promissory Note Payable PromissoryNotePayable	200000	usd
CY2022Q4	bicx	Promissory Note Payable PromissoryNotePayable	200000	usd
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable	100000	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	76122	usd
CY2023Q4	bicx	Other Notes Payable Promissory OtherNotesPayablePromissory	49605	usd
CY2022Q4	bicx	Other Notes Payable Promissory OtherNotesPayablePromissory	0	usd
CY2023Q4	bicx	Other Notes Payables Promissory OtherNotesPayablesPromissory	69104	usd
CY2022Q4	bicx	Other Notes Payables Promissory OtherNotesPayablesPromissory	0	usd
CY2023Q4	bicx	Others Notes Payables Promissory OthersNotesPayablesPromissory	84015	usd
CY2022Q4	bicx	Others Notes Payables Promissory OthersNotesPayablesPromissory	0	usd
CY2023Q4	bicx	Others Notes Payables Promissory Other OthersNotesPayablesPromissoryOther	82546	usd
CY2022Q4	bicx	Others Notes Payables Promissory Other OthersNotesPayablesPromissoryOther	0	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	606750	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	297602	usd
CY2023	bicx	Interest Expenses Related Party InterestExpensesRelatedParty	692586	usd
CY2022	bicx	Interest Expenses Related Party InterestExpensesRelatedParty	935806	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	477436	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	477436	usd
CY2023Q4	bicx	Accumulated Interest Notes Payable AccumulatedInterestNotesPayable	478920	usd
CY2022Q4	bicx	Accumulated Interest Notes Payable AccumulatedInterestNotesPayable	332567	usd
CY2023Q4	bicx	Advances From Related Parties Current AdvancesFromRelatedPartiesCurrent	999088	usd
CY2022Q4	bicx	Advances From Related Parties Current AdvancesFromRelatedPartiesCurrent	990637	usd
CY2023Q4	bicx	Accumulated Interest On Eidl Loan AccumulatedInterestOnEidlLoan	5675	usd
CY2022Q4	bicx	Accumulated Interest On Eidl Loan AccumulatedInterestOnEidlLoan	5860	usd
CY2023	bicx	Schedule Of Future Principle Payments ScheduleOfFuturePrinciplePayments	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,651</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2029 and after</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">69,201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">72,466</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Next Rolling Twelve Months CapitalLeasesFutureMinimumPaymentsReceivableNextRollingTwelveMonths	0	usd
CY2023Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling Year Two CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingYearTwo	0	usd
CY2023Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling Year Three CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingYearThree	16	usd
CY2023Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling Year Four CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingYearFour	1598	usd
CY2023Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling Year Five CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingYearFive	1651	usd
CY2023Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling After Year Five CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingAfterYearFive	69201	usd
CY2023Q4	us-gaap	Capital Leases Future Minimum Payments Receivable CapitalLeasesFutureMinimumPaymentsReceivable	72466	usd
CY2023	bicx	Royalty Agreements Description RoyaltyAgreementsDescription	each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments
CY2023	bicx	Expected Life Of Arrangement ExpectedLifeOfArrangement	P15Y
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	7171200	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	477436	usd
CY2023	bicx	Share Based Goods And Nonemployee Services Transactions Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionsValuationMethodExpectedTerm1	P5Y
CY2023	bicx	Share Based Goods And Nonemployee Services Transactions Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionsValuationMethodExpectedDividendRate	0.0000	pure
CY2022	bicx	Share Based Goods And Nonemployee Services Transactions Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionsValuationMethodExpectedDividendRate	0.0000	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	815351	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.85
CY2022	bicx	Outstanding Beginning OutstandingBeginning	P4Y10M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	795115	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	350	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.60
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	59057	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.07
CY2022	bicx	Sharebased Compensation Arrangement By Sharebased Payment Grant In Period SharebasedCompensationArrangementBySharebasedPaymentGrantInPeriod	P4Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	874058	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
CY2023	bicx	Sharebased Compensation Arrangement By Sharebased Payment Grant In Period SharebasedCompensationArrangementBySharebasedPaymentGrantInPeriod	P4Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	891443	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.41
CY2023	bicx	Outstanding At Ending OutstandingAtEnding	P3Y
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	889151	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.41
CY2023	bicx	Exercisable At End Of Year ExercisableAtEndOfYear	P3Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.78
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63941	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	111079	usd
CY2023	bicx	Stock Compensation Expense Unamortized StockCompensationExpenseUnamortized	3796	usd
CY2023	bicx	Weighted Average Remaining Life WeightedAverageRemainingLife	P5M
CY2023	bicx	Schedule Of Assumptions In Warrants Under Black Scholes Option Pricing Model ScheduleOfAssumptionsInWarrantsUnderBlackScholesOptionPricingModel	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3.60–4.73</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">% </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.94</td><td style="vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected term (years)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3.00 – 4.00</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">158.00–174.29%</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">% </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">139.37</td><td style="vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022	bicx	Share Based Goods And Nonemployee Services Transactions Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionsValuationMethodExpectedTerm1	P3Y
CY2023Q4	bicx	Notes Payables Related Parties Current And Noncurrent NotesPayablesRelatedPartiesCurrentAndNoncurrent	1683453	usd
CY2022Q4	bicx	Notes Payables Related Parties Current And Noncurrent NotesPayablesRelatedPartiesCurrentAndNoncurrent	1077088	usd
CY2023	bicx	Non Controlling Interest Beginning Balance NonControllingInterestBeginningBalance	-125257	usd
CY2023	bicx	Net Loss Attributable To The Non Controlling Interest NetLossAttributableToTheNonControllingInterest	-3577	usd
CY2023	bicx	Non Controlling Interest Ending Balance NonControllingInterestEndingBalance	-128834	usd
CY2022	bicx	Non Controlling Interest Beginning Balance NonControllingInterestBeginningBalance	-117838	usd
CY2022	bicx	Net Loss Attributable To The Non Controlling Interest NetLossAttributableToTheNonControllingInterest	-7419	usd
CY2022	bicx	Non Controlling Interest Ending Balance NonControllingInterestEndingBalance	-125257	usd
CY2022Q1	bicx	First Payment Owed FirstPaymentOwed	145000	usd
CY2023	bicx	First Payment Owed FirstPaymentOwed	0	usd
CY2023	bicx	Compensation For Services Descriptions CompensationForServicesDescriptions	As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month
CY2023	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	57412	usd
CY2023	bicx	Recognized Gain Loss On Contingency RecognizedGainLossOnContingency	-322000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	bicx	Schedule Of Different Tax Rate ScheduleOfDifferentTaxRate	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Provision at statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">State taxes, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.89</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.56</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.81 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.02 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Interest addback</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2.28 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2.93 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nondeductible and other items</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.20 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.34 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23.60 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(22.27 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)%</td></tr></tbody></table>
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0589	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0556	pure
CY2023	bicx	Other Increase Decrease OtherIncreaseDecrease	-0.0081	pure
CY2022	bicx	Other Increase Decrease OtherIncreaseDecrease	-0.0102	pure
CY2023	bicx	Interest Addback InterestAddback	-0.0228	pure
CY2022	bicx	Interest Addback InterestAddback	-0.0293	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0020	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0034	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2360	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2227	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0000	pure
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7598	usd
CY2023Q4	bicx	Stock Options Issued For Services StockOptionsIssuedForServices	2077903	usd
CY2022Q4	bicx	Stock Options Issued For Services StockOptionsIssuedForServices	1988251	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7969941	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7796815	usd
CY2023Q4	bicx	Capitalization Under Section Act CapitalizationUnderSectionAct	510302	usd
CY2022Q4	bicx	Capitalization Under Section Act CapitalizationUnderSectionAct	224416	usd
CY2023Q4	bicx	Accrual To Cash AccrualToCash	684411	usd
CY2022Q4	bicx	Accrual To Cash AccrualToCash	478860	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	185316	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	202593	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11427873	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10698533	usd
CY2023Q4	bicx	Royalty Obligation RoyaltyObligation	-172730	usd
CY2022Q4	bicx	Royalty Obligation RoyaltyObligation	-306334	usd
CY2023Q4	bicx	Right To Use Assets RightToUseAssets	-27222	usd
CY2022Q4	bicx	Right To Use Assets RightToUseAssets	-55447	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	199952	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	361781	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	11227921	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10336752	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11227921	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10336752	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11227921	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10336752	usd
CY2023	bicx	Federal Net Operating Losses Carryforward Description FederalNetOperatingLossesCarryforwardDescription	the Company had federal net operating loss carryforwards of approximately $23.0 million, of which $9.3 million, if not utilized, expire beginning by 2029
CY2023	bicx	Cumulative Change In Ownership CumulativeChangeInOwnership	0.50	pure

Files In Submission

Name	View Source	Status
0001477932-24-001705-index-headers.html	Edgar Link	pending
0001477932-24-001705-index.html	Edgar Link	pending
0001477932-24-001705.txt	Edgar Link	pending
0001477932-24-001705-xbrl.zip	Edgar Link	pending
bicx-20231231.xsd	Edgar Link	pending
bicx-20231231_def.xml	Edgar Link	unprocessable
bicx_10k.htm	Edgar Link	pending
bicx_ex311.htm	Edgar Link	pending
bicx_ex312.htm	Edgar Link	pending
bicx_ex321.htm	Edgar Link	pending
bicx_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
bicx-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bicx_10k_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bicx-20231231_cal.xml	Edgar Link	unprocessable
bicx-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BICX
BioCorRx Inc. Stock $bicx

2024 Q1 Form 10-K Financial Statement

#000147793224001705 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BICX BioCorRx Inc. Stock $bicx

2024 Q1 Form 10-K Financial Statement

#000147793224001705 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BICX
BioCorRx Inc. Stock $bicx